Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the transaction, the chief operating officer now owns 595,580 shares in the company, valued at approximately $6,843,214.20. The trade was a 14.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Stock Down 1.7 %

Shares of NASDAQ:ROIV opened at $11.80 on Friday. The firm has a market capitalization of $8.59 billion, a PE ratio of 2.09 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06. The company has a 50-day moving average price of $11.91 and a two-hundred day moving average price of $11.52.

Analyst Ratings Changes

Several analysts have recently issued reports on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. Bank of America increased their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Hedge Funds Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Clearbridge Investments LLC boosted its position in Roivant Sciences by 51.3% during the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock worth $19,666,000 after purchasing an additional 630,712 shares during the period. Point72 Asset Management L.P. boosted its position in Roivant Sciences by 40.1% during the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after purchasing an additional 185,226 shares during the period. Exchange Traded Concepts LLC bought a new position in Roivant Sciences during the third quarter worth about $2,267,000. TOMS Capital Investment Management LP bought a new position in Roivant Sciences during the third quarter worth about $46,333,000. Finally, Loomis Sayles & Co. L P boosted its position in Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock worth $45,147,000 after purchasing an additional 458,601 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.